GoldenGolden
Winston Pharmaceuticals

Winston Pharmaceuticals

Winston Pharmaceuticals is a biotechnology company developing pain management products.

All edits

Edits on 19 Mar, 2021
Golden AI"adding inverse field"
Golden AI edited on 19 Mar, 2021
Edits made to:
Infobox (+1 properties)
Infobox
SBA Awards
WINSTON PHARMACEUTICALS, INC. SBIR Phase I Award,
Edits on 6 Mar, 2021
Golden AI"Auto-imported"
Golden AI edited on 6 Mar, 2021
Edits made to:
Infobox (+1 properties)
Infobox
D-U-N-S Number
117754601
Edits on 17 Mar, 2019
Niroj Manandhar
Niroj Manandhar approved a suggestion from Golden's AI on 17 Mar, 2019
Edits made to:
Article (+22/-22 characters)
Article

Winston has multiple pain medications in investigational product pipeline for conditions like Episodic cluster headache, PHN (Postherpetic NeuralgiaPostherpetic Neuralgia) of the trigeminal nerve, chronic migraine headache, Chron’s disease, Osteoarthritis pain, and End-stage cancer pain. Civamide Sterile Solution for End-stage pain is in pre-clinical test phase while other medications are in different clinical trial phases.

Niroj Manandhar
Niroj Manandhar approved a suggestion from Golden's AI on 17 Mar, 2019
Edits made to:
Article (+11/-11 characters)
Article

Winston has multiple pain medications in investigational product pipeline for conditions like Episodic cluster headache, PHN (Postherpetic Neuralgia) of the trigeminal nerve, chronic migraine headache, Chron’s disease, Osteoarthritis pain, and End-stage cancer paincancer pain. Civamide Sterile Solution for End-stage pain is in pre-clinical test phase while other medications are in different clinical trial phases.

Niroj Manandhar
Niroj Manandhar approved a suggestion from Golden's AI on 17 Mar, 2019
Edits made to:
Article (+8/-8 characters)
Article

Winston Pharmaceuticals is an IllinoisIllinois based biotechnology company developing therapeutics to alleviate pain for conditions without approved prescription medication or imperfect therapies. Winston aims to create a long term pain relief medication for patients of neuropathic pain, post-mastectomy pain, diabetic neuropathy pain, and phantom limb pain. The primary medicine candidate uses an active ingredient which depletes or interferes with the action of the neuroactive transmitter which decreases the ability of sensory fibers to transmit pain stimuli.

Niroj Manandhar
Niroj Manandhar approved a suggestion from Golden's AI on 17 Mar, 2019
Edits made to:
Article (+13/-13 characters)
Article

The company plans to distribute products in the United StatesUnited States exclusively and license its products for sale in other countries.

Niroj Manandhar
Niroj Manandhar approved a suggestion from Golden's AI on 17 Mar, 2019
Edits made to:
Article (+14/-14 characters)
Article

Winston has multiple pain medications in investigational product pipeline for conditions like Episodic cluster headache, PHN (Postherpetic Neuralgia) of the trigeminal nerve, chronic migraine headache, Chron’s disease, OsteoarthritisOsteoarthritis pain, and End-stage cancer pain. Civamide Sterile Solution for End-stage pain is in pre-clinical test phase while other medications are in different clinical trial phases.

Edits on 15 Mar, 2019
Niroj Manandhar"initial article commit"
Niroj Manandhar edited on 15 Mar, 2019
Edits made to:
Infobox (+1/-3 properties)
Timeline (+1 events) (+429 characters)
Description (+13/-1 characters)
Article (+1729 characters)
People (+4 rows) (+8 cells) (+227/-12 characters)
Further reading (+1 rows) (+4 cells) (+85 characters)
Related Topics (+1 topics)
Topic thumbnail

Winston Pharmaceuticals

ABiotechnology company developing pain management products

Article

Winston Pharmaceuticals is an Illinois based biotechnology company developing therapeutics to alleviate pain for conditions without approved prescription medication or imperfect therapies. Winston aims to create a long term pain relief medication for patients of neuropathic pain, post-mastectomy pain, diabetic neuropathy pain, and phantom limb pain. The primary medicine candidate uses an active ingredient which depletes or interferes with the action of the neuroactive transmitter which decreases the ability of sensory fibers to transmit pain stimuli.

Product

Civamide, a TRPV-1 (Transient Receptor Potential Vanilloid-1) is a proprietary chemical compound used in many of the company’s products. It affects type-C neurons by binding to a TRPV-1 membrane receptor to inhibit pain transmission. Other anesthesia's block all sensory neurons, but civamide is capable of blocking pain sensation only while allowing touch, heat, pressure, and vibration sensors to work. As of March 2019, Civamide application as oral intake, topical cream, nasal solution or patch form are in development.

Winston has multiple pain medications in investigational product pipeline for conditions like Episodic cluster headache, PHN (Postherpetic Neuralgia) of the trigeminal nerve, chronic migraine headache, Chron’s disease, Osteoarthritis pain, and End-stage cancer pain. Civamide Sterile Solution for End-stage pain is in pre-clinical test phase while other medications are in different clinical trial phases.

The company plans to distribute products in the United States exclusively and license its products for sale in other countries.

History

Joel E. Bernstein founded the company in 1998 and is headquartered in Vernon Hills, Illinois.

People

Name
Role
Related Golden topics

Barry Hollingsworth

Chief Financial Officer.

David A. Henninger

Vice President, Operations

MatthewJoel PerryE. Bernstein

Founder and Chief Executive Officer

Scott B. Phillips

Senior Vice President, Scientific Affairs

Scott B. Phillips

Senior Vice President

Further reading

Title
Author
Link
Type

SID 341155570 - PubChem

Pubchem

Web

Infobox
Industry
Related Topics
Timeline

March 15, 2019

NIH awards SBIR grant to Winston Pharma to investigate treatment for PHN of trigeminal nerve

The National Institutes of Health (NIH) has awards Winston Pharmaceuticals,, a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, a grant under the Small Business Innovation Research (SBIR) programme supporting the development of Civamide, a proprietary TRPV-1 receptor modulator,

Edits on 4 Feb, 2019
Golden AI"Import data"
Golden AI edited on 4 Feb, 2019
Edits made to:
People (+1 rows) (+2 cells) (+20 characters)
People

Name
Role
Related Golden topics

Matthew Perry

Founder

Edits on 21 Jan, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan, 2019
Edits on 16 Jan, 2019
Golden AI"Import data"
Golden AI edited on 16 Jan, 2019
Edits on 9 Jan, 2019
Golden AI
Golden AI edited on 9 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 Dec, 2018
Golden AI"Import data"
Golden AI edited on 12 Dec, 2018
Edits made to:
Infobox (+2 properties)
People (+1 rows) (+2 cells) (+24 characters)
Categories (+1 topics)
People

Name
Role
Related Golden topics

Richard B. Alman

Investor

Infobox
Categories
Edits on 1 Sep, 2018
Golden AI"Update description"
Golden AI edited on 1 Sep, 2018
Edits made to:
Description (+45/-21 characters)
Topic thumbnail

Winston Pharmaceuticals

Biotechnology company

A company developing pain management products

Edits on 19 Jul, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul, 2018
Edits on 29 Jun, 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun, 2018
Edits on 29 May, 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May, 2018
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Winston Pharmaceuticals

Biotechnology company

Categories
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.